NEW YORK (Reuters Health) – Concerns that bisphosphonate drugs used to treat osteoporosis might increase the risk of developing esophageal cancer have been put to rest by a…
NEW YORK (Reuters Health) – The response rate with standard treatment of hepatitis C infection is doubled when a hepatitis C virus (HCV) protease inhibitor, boceprevir, is added…
NEW YORK (Reuters Health) – Patients on warfarin need not discontinue treatment when they have a fecal occult blood test (FOBT), as it does not affect the predictive…
NEW YORK (Reuters Health) – After ruling out an upper gastrointestinal (GI) source of bleeding, patients with serious hematochezia should undergo colonoscopy within the next few days. But…
NEW YORK (Reuters Health) – Disinfectant use and other simple interventions are helpful in combating Clostridium difficile, a major infectious cause of healthcare-associated diarrhea, researchers report in a…
NEW YORK (Reuters Health) – Oral zinc is not an effective treatment for acute gastroenteritis (AGE) in children from developed countries, suggest results of a randomized, double-blind, placebo-controlled…
NEW YORK (Reuters Health) – During the first year of treatment for chronic hepatitis B, tenofovir and entecavir are the most effective antiviral agents available, according to the…
NEW YORK (Reuters Health) – Patients infected with hepatitis C virus (HCV) type 1 who have a slow response to pegylated interferon-alfa and ribavirin can benefit from continuing…
NEW YORK (Reuters Health) – HIV-positive patients taking efavirenz are at risk for clinically significant vitamin D deficiency, and for excessive bone turnover if they are taking tenofovir,…
NEW YORK (Reuters Health) – The risk of developing obesity-related cancer such as breast cancer or prostate cancer is apparently not curtailed in patients who undergo bariatric surgery…